Abstract
Rituximab is used in the treatment of lymphoma and autoimmune diseases, for which late-onset neutropenia (LON) were reported. LON-related mechanisms remain unclear. To obtain insights into the mechanisms, we assessed serum, peripheral blood and bone marrow (BM) samples of a patient with LON. Factors classically associated with neutropenia such as anti-neutrophil antibodies, T-LGL, soluble Fas Ligand were not detectable. We then evaluated the kinetics of various cytokines involved in B-cell and granulocyte homeostasis. We found that LON is related to a lack of granulopoiesis in the BM that coincides with a very high level of BAFF, a strong stimulator of B-cell recovery, and hypothesized a hematopoietic lineage competition due to an excessive B-cell recovery in the BM by promotion of B-cell lymphopoiesis over granulopoiesis within common developmental niches. Assessment of serum BAFF levels following rituximab could detect patients at risk of developing LON.References
- Cairoli R, Grillo G, Tedeschi A, D’Avanzo G, Marenco P, Morra E. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica. 2004; 89:361-363. PubMedGoogle Scholar
- Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol. 2003; 121:913-918. PubMedhttps://doi.org/10.1046/j.1365-2141.2003.04385.xGoogle Scholar
- Lemieux B, Tartas S, Traulle C. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2004; 33:921-923. PubMedhttps://doi.org/10.1038/sj.bmt.1704467Google Scholar
- Papadaki T, Stamatopoulos K, Stavroyianni N, Paterakis G, Phisphis M, Stefanoudaki-Sofianatou K. Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases. Leuk Res. 2002; 26:597-600. PubMedhttps://doi.org/10.1016/S0145-2126(01)00183-7Google Scholar
- Saikia TK, Menon H, Advani SH. Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin’s lymphoma and corrected with IVIG. Ann Oncol. 2001; 12:1493-1494. PubMedhttps://doi.org/10.1023/A:1012500524758Google Scholar
- Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med. 2003; 348:2691-2694. PubMedhttps://doi.org/10.1056/NEJM200306263482620Google Scholar
- Dunleavy K, Hakim F, Kim HK. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood. 2005; 106:795-802. PubMedhttps://doi.org/10.1182/blood-2004-08-3198Google Scholar
- Ma Q, Jones D, Borghesani PR. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A. 1998; 95:9448-9453. PubMedhttps://doi.org/10.1073/pnas.95.16.9448Google Scholar
- Osborn MJ, Ryan PL, Kirchhof N, Panoskaltsis-Mortari A, Mortari F, Tudor KS. Overexpression of murine TSLP impairs lymphopoiesis and myelopoiesis. Blood. 2004; 103:843-851. PubMedhttps://doi.org/10.1182/blood-2003-05-1557Google Scholar
- Drutskaya MS, Ortiz M, Liepinsh DJ, Kuprash DV, Nedospasov SA, Keller JR. Inhibitory effects of tumor necrosis factor on hematopoiesis seen in vitro are translated to increased numbers of both committed and multipotent progenitors in TNF-deficient mice. Exp Hematol. 2005; 33:1348-1356. PubMedhttps://doi.org/10.1016/j.exphem.2005.08.001Google Scholar
- Zhang P, Iwama A, Datta MW, Darlington GJ, Link DC, Tenen DG. Upregulation of interleukin 6 and granulocyte colony-stimulating factor receptors by transcription factor CCAAT enhancer binding protein alpha (C/EBP alpha) is critical for granulopoiesis. J Exp Med. 1998; 188:1173-1184. PubMedhttps://doi.org/10.1084/jem.188.6.1173Google Scholar
- Liu F, Poursine-Laurent J, Wu HY, Link DC. Interleukin-6 and the granulocyte colony-stimulating factor receptor are major independent regulators of granulopoiesis in vivo but are not required for lineage commitment or terminal differentiation. Blood. 1997; 90:2583-2590. PubMedGoogle Scholar
- Moore PA, Belvedere O, Orr A. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999; 285:260-263. PubMedhttps://doi.org/10.1126/science.285.5425.260Google Scholar
- Schneider P, MacKay F, Steiner V. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999; 189:1747-1756. PubMedhttps://doi.org/10.1084/jem.189.11.1747Google Scholar
- Lesley R, Xu Y, Kalled SL. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity. 2004; 20:441-453. PubMedhttps://doi.org/10.1016/S1074-7613(04)00079-2Google Scholar
- Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006; 54:723-732. PubMedhttps://doi.org/10.1002/art.21650Google Scholar
- Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B-cell activating factor of the TNF family (BAFF) after rituximab: insights into a new regulating system of BAFF production. Ann Rheum Dis. 2006. Google Scholar
- Ueda Y, Kondo M, Kelsoe G. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J Exp Med. 2005; 201:1771-1780. PubMedhttps://doi.org/10.1084/jem.20041419Google Scholar